<DOC>
	<DOCNO>NCT02617446</DOCNO>
	<brief_summary>To Assess safety , tolerability efficacy two different dos istaroxime ( 0.5 1.0 µg/kg/min ) , new agent lusitropic inotropic activity improve cardiac contraction-relaxation cycle . The 2 dos istaroxime ( 0.5 1.0 µg/kg/min ) infuse i. v. 24 hour comparison placebo , treatment Chinese Italian patient Acute Decompensated Heart Failure . In Italian patient subset Chinese patient pharmacokinetics metabolism istaroxime shall also study .</brief_summary>
	<brief_title>The Clinical Study Safety Efficacy Istaroxime Treatment Acute Decompensated Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients fulfill follow inclusion criterion screen consider study : 1 . Signed informed consent ; 2 . Male female patient 1885 year ( inclusive ) ; 3 . Admission recurrent ADHF episode dyspnea rest minimal exertion need intravenous diuretic therapy ( ≥40 mg iv . furosemide ) ; 4 . Systolic blood pressure 90 125 mmHg ( limit include ) without sign symptom hypoperfusion include cardiogenic shock , cold extremity peripheral vasoconstriction , oliguria/anuria , sign cerebral hypo perfusion confusion ; 5 . Left ventricular ( LV ) Ejection fraction ( EF ) ≤ 40 % measure 2DEchocardiography 6 . E/Ea ratio &gt; 10 7 . BNP ≥ 350pg/mL NTproBNP ≥1400 pg/mL 8 . Adequate echocardiography window ( defined visualization least 13/16 segment leave ventricle ) ; Any follow criterion establish screen would render patient ineligible study : 1 . Pregnant breastfeed woman ( woman child bear potential must result negative pregnancy test record prior study drug administration ) 2 . Current ( within 12 hour prior screen ) plan ( completion study drug infusion ) treatment iv . therapy , include vasodilator ( include nitrate nesiritide ) , positive inotropic agent vasopressor 3 . Current need mechanical support ( intraaortic balloon pump , endotracheal intubation , mechanical ventilation , ventricular assist device ) , 4 . Ongoing treatment oral digoxin . Patient treat digoxin within last week , randomise plasma concentration digoxin test randomization value le 0.5 ng/ml . 5 . History hypersensitivity study medication relate medication 6 . Diagnosis cardiogenic shock within past month ; 7 . Acute coronary syndrome stroke within past 3 month ; 8 . Coronary artery bypass graft percutaneous coronary intervention within past month plan next month ; 9 . Primary hypertrophic restrictive cardiomyopathy systemic illness know associated infiltrative heart disease ; 10 . Cor pulmonale cause rightsided HF related leave ventricular dysfunction ; 11 . Pericardial constriction active pericarditis ; 12 . Atrial fibrillation mark irregularity heart rhythm ; 13 . Life threaten ventricular arrhythmia ICD ( implantable cardioverter defibrillator ) shock within past month ; 14 . CRT ( cardiac resynchronization therapy ) , ICD pacemaker implantation within past month ; 15 . Valvular disease primary cause HF ; 16 . Heart rate &gt; 120 bpm &lt; 50 bpm 17 . Acute respiratory distress syndrome ongoing sepsis ; 18 . Fever &gt; 38° 19 . History bronchial asthma porphyria ; 20 . Donation loss blood equal exceed 500 mL , 8 week administration study medication ; 21 . Positive test HIV , Hepatitis B and/or Hepatitis C ; 22 . Participation another interventional study within past 30 day ; 23 . The following laboratory exclusion criterion , verify base result obtain within last 24 hour hospitalization : 1 . Serum creatinine &gt; 3.0 mg/dl ( &gt; 265 µmol/L ) ; 2 . Aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) &gt; 3 x upper limit normal , 3 . Hemoglobin ( Hb ) &lt; 10 g/dL , 4 . Platelet count &lt; 100,000/µL , 5 . Serum potassium &gt; 5.3 mmol/L &lt; 3.8 mmol/L ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>istaroxime</keyword>
</DOC>